Drug Profile
PF 6664178
Alternative Names: PF-06664178; PF6664178Latest Information Update: 25 Aug 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 04 May 2016 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV) (Pfizer pipeline, May 2016)
- 01 Apr 2016 Pfizer terminates a phase I trial for Solid tumours (Late-stage disease) in USA (NCT02122146)
- 01 Aug 2014 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV)